Sarcopenia en paciente oncológico: revisión de literatura

Contenido principal del artículo

MD Teresita Aguilera-Jinesta
MD Vanessa Uclés-Villalobos https://orcid.org/0000-0002-8029-8163

Keywords

Sarcopenia, Neoplasias, Debilidad Muscular

Resumen

El cáncer es una patología cada vez más común que genera altos grados de desgaste físico, emocional y psicosocial en quienes la padecen, además de importantes costos económicos para los servicios de salud. La sarcopenia, una condición caracterizada por la pérdida de masa, fuerza y función muscular de etiología multifactorial, es un factor de mal pronóstico en pacientes oncológicos. Esta afección impacta variables como las readmisiones hospitalarias postquirúrgicas, estancias prolongadas, alteración en el proceso de cicatrización, y disminución de la calidad de vida y funcionalidad. Este artículo presenta una revisión actualizada del tema y enfatiza la importancia de identificar a los pacientes con alto riesgo de desarrollar sarcopenia, con el objetivo de implementar medidas tempranas y esquemas de tratamiento oportuno.

Abstract 483 | PDF Downloads 314

Citas

1. Deutz NE, Ashurst I, Ballesteros MD, Bear DE, Cruz-Jentoft AJ, Genton L, et al. The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition. J Am Med Dir Assoc. 2019;20(1):22-27. Doi: 10.1016/j.jamda.2018.11.021

2. Colloca G, Di Capua B, Bellieni A, Cesari M, Marzetti E, Valentini V, et al. Musculoskeletal aging, sarcopenia and cancer. J Geriatr Oncol. 2019;10(3):504-509. Doi: 10.1016/j.jgo.2018.11.007

3. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al.; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. Doi: 10.1093/ageing/afy169

4. Peterson SJ, Braunschweig CA. Prevalence of Sarcopenia and Associated Outcomes in the Clinical Setting. Nutr Clin Pract. 2016;31(1):40-48. Doi: 10.1177/0884533615622537

5. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer. 2014;66(4):583-589. Doi: 10.1080/01635581.2014.894103

6. da Silva JR Jr, Wiegert E, Oliveira L, Calixto-Lima L. Different methods for diagnosis of sarcopenia and its association with nutritional status and survival in patients with advanced cancer in palliative care. Nutrition. 2019;60:48-52. Doi: 10.1016/j.nut.2018.09.003

7. Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review. Clin Nutr. 2018;37(4):1101-1113. Doi: 10.1016/j.clnu.2017.07.010

8. Molina Garrido MJ, Guillén Ponce C, Fernández Félix B, Muñoz Sánchez M, Soriano Rodríguez M, Olaverri Hernández A, et al. Detección y evaluación del papel de la sarcopenia en ancianos con cáncer tratados con quimioterapia. Proyecto ONCOSARCO. Rev Esp Geriatr Gerontol. 2017;52(3):146-151. Doi: 10.1016/j.regg.2016.02.003

9. Chindapasirt J. Sarcopenia in Cancer Patients. Asian Pac J Cancer Prev. 2015;16(18):8075-8077. Doi: 10.7314/apjcp.2015.16.18.8075

10. Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol. 2016;54:2-10. Doi: 10.1016/j.semcdb.2015.09.001

11. da Cunha LP, Silveira MN, Mendes M, Costa FO, Macedo LT, de Siqueira NS, et al. Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: A retrospective evaluation. Clin Nutr ESPEN. 2019;32:107-112. Doi: 10.1016/j.clnesp.2019.04.004

12. Uchida T, Sekine R, Matsuo K, Kigawa G, Umemoto T, Kijima K, et al. Association between low preoperative skeletal muscle quality and infectious complications following gastrectomy for gastric cancer. Surg Today. 2021;51(7):1135-1143. Doi: 10.1007/s00595-020-02225-x

13. Fuggle N, Shaw S, Dennison E, Cooper C. Sarcopenia. Best Pract Res Clin Rheumatol. 2017;31(2):218-242. Doi: 10.1016/j.berh.2017.11.007

14. Robertson HL, Michel C, Bartl L, Hamilton-Reeves JM. Sarcopenia in urologic oncology: Identification and strategies to improve patient outcomes. Urol Oncol. 2020;S1078-1439(20)30197-6. Advance online publication. Doi: 10.1016/j.urolonc.2020.05.001

15. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, et al. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020;38(3):83-93. Doi: 10.1016/j.urolonc.2019.10.006

16. Martínez-González MA, Sánchez-Villegas A. Food patterns and the prevention of depression. Proc Nutr Soc. 2016;75(2):139-146. Doi: 10.1017/S0029665116000045

17. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review. Eur J Cancer. 2016;57:58-67. Doi: 10.1016/j.ejca.2015.12.030

18. Krznarić Ž, Bender DV, Laviano A, Cuerda C, Landi F, Monteiro R, et al. A simple remote nutritional screening tool and practical guidance for nutritional care in primary practice during the COVID-19 pandemic. Clin Nutr. 2020;39(7):1983-1987. Doi: 10.1016/j.clnu.2020.05.006

19. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28-36. Doi: 10.1002/jcsm.12048

20. Gibson DJ, Burden ST, Strauss BJ, Todd C, Lal S. The role of computed tomography in evaluating body composition and the influence of reduced muscle mass on clinical outcome in abdominal malignancy: a systematic review. Eur J Clin Nutr. 2015;69(10):1079-1086. Doi: 10.1038/ejcn.2015.32

21. Rossi F, Valdora F, Bignotti B, Torri L, Succio G, Tagliafico AS. Evaluation of body Computed Tomography-determined sarcopenia in breast cancer patients and clinical outcomes: A systematic review. Cancer Treat Res Commun. 2019;21:100154. Doi: 10.1016/j.ctarc.2019.100154

22. Zakaria HM, Massie L, Basheer A, Elibe E, Boyce-Fappiano D, Shultz L, et al. Application of Morphometrics as a Predictor for Survival in Patients with Prostate Cancer Metastasis to the Spine. World Neurosurg. 2018;114
Doi: 10.1016/j.wneu.2018.03.115

23. Santos K, Gomes F, Silva S, Silva A, Pinho C. Sarcopenia en pacientes oncológicos en tratamiento Quimioterápico. Retrieved 25 May 2022.

24. Pereira-Rodríguez J, Peñaranda-Florez D, Pereira-Rodríguez R, Pereira-Rodríguez P. Cambios hemodinámicos y calidad de vida en pacientes con cáncer de próstata luego de un entrenamiento HIIT Y MICT. Ensayo clínico aleatorizado (ONCO-EXE TRIAL). Retrieved 25 May 2022.

25. Falandry C, Stefani L, Andre L, Granger M, Barbavara C, Habchi H, et al.; PROADAPT working group. Interventions to improve physical performances of older people with cancer before complex medico-surgical procedures: Protocol for an umbrella review of systematic reviews and meta-analyses. Medicine (Baltimore). 2020;99(39). Doi: 10.1097/MD.000000000002

Artículos más leídos del mismo autor/a